222 related articles for article (PubMed ID: 26519433)
1. Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology.
Rosenberger AF; Hilhorst R; Coart E; García Barrado L; Naji F; Rozemuller AJ; van der Flier WM; Scheltens P; Hoozemans JJ; van der Vies SM
J Alzheimers Dis; 2016; 49(4):927-43. PubMed ID: 26519433
[TBL] [Abstract][Full Text] [Related]
2. P38 MAP kinase is activated at early stages in Alzheimer's disease brain.
Sun A; Liu M; Nguyen XV; Bing G
Exp Neurol; 2003 Oct; 183(2):394-405. PubMed ID: 14552880
[TBL] [Abstract][Full Text] [Related]
3. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology.
Griffin RJ; Moloney A; Kelliher M; Johnston JA; Ravid R; Dockery P; O'Connor R; O'Neill C
J Neurochem; 2005 Apr; 93(1):105-17. PubMed ID: 15773910
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models.
Martiskainen H; Viswanathan J; Nykänen NP; Kurki M; Helisalmi S; Natunen T; Sarajärvi T; Kurkinen KM; Pursiheimo JP; Rauramaa T; Alafuzoff I; Jääskeläinen JE; Leinonen V; Soininen H; Haapasalo A; Huttunen HJ; Hiltunen M
Neurobiol Aging; 2015 Feb; 36(2):1221.e15-28. PubMed ID: 25281018
[TBL] [Abstract][Full Text] [Related]
5. Impaired Src signaling and post-synaptic actin polymerization in Alzheimer's disease mice hippocampus--linking NMDA receptors and the reelin pathway.
Mota SI; Ferreira IL; Valero J; Ferreiro E; Carvalho AL; Oliveira CR; Rego AC
Exp Neurol; 2014 Nov; 261():698-709. PubMed ID: 25128699
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain.
Kurbatskaya K; Phillips EC; Croft CL; Dentoni G; Hughes MM; Wade MA; Al-Sarraj S; Troakes C; O'Neill MJ; Perez-Nievas BG; Hanger DP; Noble W
Acta Neuropathol Commun; 2016 Mar; 4():34. PubMed ID: 27036949
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase activity profiling of postmortem human brain tissue.
Hoozemans JJ; Hilhorst R; Ruijtenbeek R; Rozemuller AJ; van der Vies SM
Neurodegener Dis; 2012; 10(1-4):46-8. PubMed ID: 22343098
[TBL] [Abstract][Full Text] [Related]
8. S6 kinase phosphorylated at T229 is involved in tau and actin pathologies in Alzheimer's disease.
Sonoda Y; Tooyama I; Mukai H; Maeda K; Akiyama H; Kawamata T
Neuropathology; 2016 Aug; 36(4):325-32. PubMed ID: 26582459
[TBL] [Abstract][Full Text] [Related]
9. Distribution, levels, and activation of MEK1 in Alzheimer's disease.
Zhu X; Sun Z; Lee HG; Siedlak SL; Perry G; Smith MA
J Neurochem; 2003 Jul; 86(1):136-42. PubMed ID: 12807433
[TBL] [Abstract][Full Text] [Related]
10. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease.
Bossers K; Wirz KT; Meerhoff GF; Essing AH; van Dongen JW; Houba P; Kruse CG; Verhaagen J; Swaab DF
Brain; 2010 Dec; 133(Pt 12):3699-723. PubMed ID: 20889584
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia.
Thal DR; Holzer M; Rüb U; Waldmann G; Günzel S; Zedlick D; Schober R
Exp Neurol; 2000 May; 163(1):98-110. PubMed ID: 10785448
[TBL] [Abstract][Full Text] [Related]
12. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.
Imahori K; Uchida T
J Biochem; 1997 Feb; 121(2):179-88. PubMed ID: 9089387
[TBL] [Abstract][Full Text] [Related]
13. Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer's disease-related microvascular cerebral amyloid angiopathy.
Merlini M; Wanner D; Nitsch RM
Acta Neuropathol; 2016 May; 131(5):737-52. PubMed ID: 26988843
[TBL] [Abstract][Full Text] [Related]
14. The protein tyrosine kinase, fyn, in Alzheimer's disease pathology.
Shirazi SK; Wood JG
Neuroreport; 1993 Apr; 4(4):435-7. PubMed ID: 8388744
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
16. Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.
Gu GJ; Wu D; Lund H; Sunnemark D; Kvist AJ; Milner R; Eckersley S; Nilsson LN; Agerman K; Landegren U; Kamali-Moghaddam M
J Alzheimers Dis; 2013; 33(3):699-713. PubMed ID: 23001711
[TBL] [Abstract][Full Text] [Related]
17. Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer's disease patients according to Braak stage.
Carter TL; Rissman RA; Mishizen-Eberz AJ; Wolfe BB; Hamilton RL; Gandy S; Armstrong DM
Exp Neurol; 2004 Jun; 187(2):299-309. PubMed ID: 15144856
[TBL] [Abstract][Full Text] [Related]
18. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.
Mouton-Liger F; Paquet C; Dumurgier J; Lapalus P; Gray F; Laplanche JL; Hugon J;
Biol Psychiatry; 2012 May; 71(9):829-35. PubMed ID: 22281122
[TBL] [Abstract][Full Text] [Related]
19. GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients.
Nicolia V; Ciraci V; Cavallaro RA; Ferrer I; Scarpa S; Fuso A
Curr Alzheimer Res; 2017; 14(7):753-759. PubMed ID: 28176663
[TBL] [Abstract][Full Text] [Related]
20. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
